Comparison
Ashwagandha vs PT-141
Side-by-side of Ashwagandha and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Ashwagandha
Ashwagandha supplement guide: KSM-66 and Sensoril extracts at 300-600 mg/day cut morning cortisol and stress in RCTs. Dose, side effects, testosterone data.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
Ashwagandha
- •Reduces morning serum cortisol by ~20 to 30% at 300 to 600 mg/day standardized extract over 8 weeks
- •Lowers subjective stress on DASS-21 and PSS scales versus placebo in chronically stressed adults
- •Modest grip-strength and 1-RM gains of ~5 to 8% in trained men when paired with resistance training
- •Improves self-reported sleep quality and onset latency in adults with insomnia symptoms
- •Small testosterone increases (~10 to 15%) reported in stressed or subfertile men, less clear in healthy populations
- •May raise free T3 and T4; can interact with levothyroxine and unmask subclinical hyperthyroidism
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | Ashwagandha | PT-141 |
|---|---|---|
| Category | natural | peptide |
| Also known as | Withania somnifera, KSM-66, Sensoril | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 10 | 2.7 |
| Typical dose (mg) ↗ | 600 | 1.75 |
| Dosing frequency | daily | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral | subcutaneous |
| Onset (hr) | 2 | 0.75 |
| Peak (hr) | - | 1.5 |
| Molecular weight | - | 1025.18 |
| Molecular formula | - | C50H68N14O10 |
| Mechanism | GABAergic modulation and HPA-axis attenuation; withanolides reduce cortisol secretion and inhibit NF-kB signaling. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | Dietary supplement in most jurisdictions; regulated in Denmark | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Not recommended | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | - | 189691-06-3 |
| PubChem CID | - | 9941379 |
| Wikidata | Q310109 | Q422059 |
Safety profile
Ashwagandha
Common side effects
- mild GI upset
- drowsiness
- headache
Contraindications
- pregnancy
- autoimmune disease (theoretical immune stimulation)
- hyperthyroidism
- concurrent sedative use
Interactions
- benzodiazepines: additive CNS depression(moderate)
- thyroid hormone (levothyroxine): may raise T3/T4, altering dose requirements(moderate)
- immunosuppressants: theoretical antagonism via immune stimulation(moderate)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
Ashwagandha comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is stress and HPA-axis regulation, pick Ashwagandha.
- → If your priority is focus or working memory, pick Ashwagandha.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you want to avoid research-only / gray-market sourcing, Ashwagandha is the more accessible choice.
Default choice: Ashwagandha. Lower friction to source, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Ashwagandha and PT-141?
Ashwagandha and PT-141 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Ashwagandha or PT-141?
Ashwagandha half-life is 10 hours; PT-141 half-life is 2.7 hours.
Can you stack Ashwagandha with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper